New quarterly report expected Apr 21, 2026. Report will refresh after results.
D
Danaher Corporation
DHR · Healthcare
Q4 FY2025
Earning ended Dec 31, 2025Report generated Mar 15, 2026
Danaher Is the Right Business at the Wrong Price
The market is debating whether the bioprocessing cycle has troughed — but that's the wrong question; the right question is whether the current multiple can be justified even after a full recovery materializes, and the math suggests it cannot without a cell-and-gene therapy revenue contribution that is still years from being visible in reported numbers.
Flowly Score
Apr 16 Close
-33%$193.78
Fair Value
$130.00
53
Averageat $193.78
Business Strength8/10
A triple-locked moat — regulatory switching costs, consumable attachment, and a four-decade operational culture — puts this in genuinely rare company; the only reason it's not a 9 is that biopharma cycle dependence and China erosion represent real, structural pressure points on the moat's edges.
Financial Resilience8/10
Thirty-four consecutive years of converting every dollar of net income into more than a dollar of free cash flow is one of the most underappreciated balance sheet facts in large-cap healthcare; the leverage load is real but sits comfortably against a cash engine this consistent and a current liquidity position that doubled year-over-year.
Growth & Trajectory6/10
The core growth story is recovering, not yet recovered — bioprocessing is leading the way back while life sciences consumables and academic spending lag, and the biologics superseding small molecules narrative is structurally compelling but will be lumpy in execution rather than linear in delivery.
Valuation3/10at $187.32
Every DCF scenario — even the one generous enough to assume everything goes right — prices this stock above intrinsic value, and the current multiple sits at the high end of a five-year range during a period of declining ROIC and contracting revenue; the market is paying for a recovery that hasn't arrived and a supercycle that's still hypothetical.
Risk5/10
The moat is durable but not invincible — China import substitution is a slow structural bleed, the shift toward continuous bioprocessing could partially undermine Cytiva's batch-process consumable thesis, and the valuation itself is a risk: there's very little margin for disappointment when the multiple demands perfection.
Danaher is genuinely one of the better-constructed industrial businesses on the planet: an installed base that earns annuity-like consumable cash flows locked inside regulatory workflows that customers cannot escape without enduring re-validation ordeals, layered over an operational culture that systematically creates value from acquisitions rather than destroying it. The quality is not in dispute. What's in dispute is whether any price is justified when the business is operating at ROIC below its cost of capital and all three valuation scenarios point to meaningful downside from current levels. Quality and price are not the same variable — and right now they are working in opposite directions. The trajectory is genuinely improving. Three consecutive quarters of pharma end-market growth, bioprocessing consumables inflecting toward high-single-digit growth, and Cytiva sitting at the center of every major CDMO expansion are all real signals. The biologics revolution — with biologic drugs now surpassing small molecules in global revenue for the first time — creates a structural tailwind that should compound Danaher's consumable volumes for the better part of a decade. The optionality embedded in the cell-and-gene therapy buildout is meaningful and underappreciated. But 'improving' and 'priced for improvement' are not the same thing either, and right now the market has already written the recovery into the multiple before the earnings revisions have followed. The single most concrete risk is not China, not Sartorius competition, not regulatory disruption — it is the valuation itself. A business earning a below-cost-of-capital return on invested capital, trading at a peak-like multiple, with all DCF scenarios showing downside, has almost no room for error. If biopharma capital spending softens again — whether from pipeline disappointments, drug pricing policy pressure, or simply another inventory cycle — the multiple compression would be swift and the downside significant. The moat will survive; the shareholder experience might not.